Cansino Biologics Inc. (688185.SH) stated on the investor interaction platform on June 19th that the necessary preclinical work for the company's combination disease-enhanced vaccine (upgraded version) to apply for clinical approval in Indonesia is underway.
康希诺(688185.SH)：结合病加强疫苗(升级版本)正在开展于印尼申请临床批件的必要前置工作
Cansino Biologics Inc. (688185.SH): The necessary preparatory work for the clinical application of the upgraded version of the combined disease-strengthening vaccine is being carried out in Indonesia.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.